Please login to the form below

Not currently logged in

pulmonary fibrosis

This page shows the latest pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions. Roche’s idiopathic pulmonary fibrosis drug Esbriet will be available routinely on the NHS in England and Wales, but only for patients with ... According to medical charity Action Pulmonary

Latest news

More from news
Approximately 7 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis. ... Its novel therapy is an inhaled formulation of

  • Deal Watch June 2016 Deal Watch June 2016

    pulmonary fibrosis (IPF) with cough. ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219, oral P2X3 antagonist for chronic cough (p2b) and idiopathic pulmonary fibrosis (p2) with cough, and other compounds.

  • Pharma deals in August 2015 Pharma deals in August 2015

    PRM 151 is under development for the treatment of idiopathic pulmonary fibrosis. ... Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma. ... Company acquisition. 840. Galecto Biotech / BMS. TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    For example, a technology originally intended to monitor the presence of lung fibrosis in idiopathic pulmonary fibrosis (IPF) but then finding utility in other fibrotic lung diseases. ... Keeping with the example of fibrosis, if the targets are viable,

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...